PDCD1 and neoplasm: Their research revealed that PD‐1/PD‐L1 interaction between myeloid cells (mPD‐1) and tumor cells (tPD‐L1) activates SHP2, which in turn antagonizes the IFN‐I and STAT1 pathway.